Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of SBRT and CDX-1127 in Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
MAIN INCLUSION CRITERIA~Males, Age ≥ 18 years.~Participants must have histologically-proven prostrate adenocarcinoma that is castrate-resistant. Progressive disease is defined by one or more of the following:~* A rise in PSA on two successive determinations at least one week apart and PSA level ≥2ng/ml.~* Soft-tissue progression defined by RECIST 1.1.~* Bone disease progression defined by PCWG2 with two or more new lesions on bone scan.~Patients must have castrate levels of testosterone (\<50 ng/dl \[1.74 nmol/l\]).~Patients must have undergone orchiectomy, or have been on LHRH agonists or antagonists, for at least 3 months prior to drug initiation. Patients on LHRH agonists/antagonists must remain on these agents for the duration of the study.~Clinical metastases must be present and confirmed on imaging studies.~Participants for whom radiation therapy is recommended for the prostate gland (or prostate bed nodule) and/or bone or soft tissue metastases.~SBRT may be administered to 1-4 sites and the treatment sites can include prostate gland (or prostate bed nodule for post-prostatectomy patients), bone metastases, and soft tissue metastases. Participants must have at least one site of disease that will be both irradiated with SBRT and biopsied to evaluate immunological outcomes.~ECOG performance status 0-2.~Adequate hepatic and renal function.~MAIN EXCLUSION CRITERIA~Prior malignancies, that will affect the completion and interpretation of the study.~Patients with active CNS metastases from prostate cancer.~Patients who are currently receiving systemic cytotoxic chemotherapy, radiation, or other experimental therapy, or who have received this therapy within the preceding 4 weeks. Patients who are currently receiving nitrosoureas or who have received this therapy within the preceding 6 weeks are excluded.~Patients who are currently receiving systemic cytotoxic chemotherapy, radiation, or other experimental therapy, or who have received this therapy within the preceding 4 weeks.~Major surgery within 4 weeks prior to the start of study treatment.~Patients who are receiving or have previously been treated CDX-1127.~HIV positivity~Evidence of active Hepatitis B virus or Hepatitis C virus.~Patients receiving the following medications at study entry or within the preceding 4 weeks (or longer, if otherwise specified) are excluded:~1. Checkpoint inhibitors (within the preceding12 weeks)~2. Allergy desensitization injections~3. Systemic corticosteroids of more than 10 mg per day of prednisone (or equivalent), administered parenterally or orally, except for physiologic replacement. Inhaled steroids (e.g. Advair®, Flovent®, Azmacort®) are not permitted. Topical corticosteroids are acceptable, including steroids with very low solubility administered nasally for local effects only (e.g. Nasonex®)~4. Any growth factors (e.g. GM-CSF, G-CSF, erythropoietin).~5. Interferon or interleukin therapy~6. Other Agents with putative immunomodulating activity. (e.g. sipuleucel-T (Provenge ®))~Other investigational drugs or investigational therapy if the patient is currently taking those drugs/therapy, or if they have received the drugs/therapy within 4 weeks prior to the start of study treatment.~Participants must not have had prior autoimmune disorders requiring cytotoxic or immunosuppressive therapy, or autoimmune disorders with visceral involvement.~Significant cardiovascular disease.~Active bleeding disorders or evidence of chronic or acute disseminated intravascular coagulation (DIC).~Concomitant therapeutic anticoagulation (i.e., warfarin) for reasons other than venous catheter patency.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A: CDX1127 & SBRT Concurrent (Type: EXPERIMENTAL): SBRT will be administered to the primary tumor and/or site of metastatic disease over a period of 5 days (Days 1-5) at a constant dose for 1-4 sites of prostate cancer involvement:30 Gy in 5 fractions of 6 Gy each for prostate gland; 25 Gy in 5 fractions for bone and/or soft tissue metastases).~Subjects will receive four doses of CDX-1127(3 mg/kg) (Days 1, 43, 64, 85). The study drug will be administered intravenously over a 90-minute time period and will be followed by a 2-hour observation period. A subject's dose of CDX-1127 will be calculated based on their actual body weight at the time of screening. A subject's dose of CDX-1127 will remain constant at each time point, unless they experience a greater than 10% change in body weight.
- Arm B: CDX1127 & SBRT Sequential; CDX1127 upfront (Type: EXPERIMENTAL): SBRT will be administered to the primary tumor and/or sites of metastatic disease over a period of 5 days (Days 22-26) at a constant dose for 1-4 sites of prostate cancer involvement:30 Gy in 5 fractions of 6 Gy each for prostate gland; 25 Gy in 5 fractions for bone and/or soft tissue metastases).~Subjects will receive four doses of CDX-1127(3 mg/kg) (Days 1, 43, 64, 85). The study drug will be administered intravenously over a 90-minute time period and will be followed by a 2-hour observation period. A subject's dose of CDX-1127 will be calculated based on their actual body weight at the time of screening. A subject's dose of CDX-1127 will remain constant at each time point, unless they experience a greater than 10% change in body weight.
- Arm C: CDX1127 & SBRT Sequential; SBRT upfront (Type: EXPERIMENTAL): SBRT will be administered to the primary tumor and/or sites of metastatic disease over a period of 5 days (Days 1-5) at a constant dose for 1-4 sites of prostate cancer involvement:30 Gy in 5 fractions of 6 Gy each for prostate gland; 25 Gy in 5 fractions for bone and/or soft tissue metastases).~Subjects will receive four doses of CDX-1127(3 mg/kg) (Days 22, 43, 64, 85). The study drug will be administered intravenously over a 90-minute time period and will be followed by a 2-hour observation period. A subject's dose of CDX-1127 will be calculated based on their actual body weight at the time of screening. A subject's dose of CDX-1127 will remain constant at each time point, unless they experience a greater than 10% change in body weight.

Based on this trial design, predict the completion outcome and termination type (if applicable).